drugset / Trial / NCT00531687
Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer
NaSingle-groupOpen-labelTreatment
Summary
Study Objectives: Primary objective * The primary objective of this study is to investigate the combination of cisplatin/gemcitabine/paclitaxel, with respect to complete remission in patients with germ cell tumours previously treated with BEP. Secondary Objectives * Overall survival * Progression free survival * Response rates (RECIST) * Duration of response * To investigate the safety of paclitaxel, gemcitabine and cisplatin in patients previously treated with BEP
Timeline
- Start
- 2007-09
- Primary completion
- 2012-02
- Completion
- 2016-10
Outcome
Outcome not reported
Stopped (Enrollment): “slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 50 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | — |